Dose-dependent pharmacokinetics of dexamethasone
- PMID: 3709651
- DOI: 10.1007/BF00614309
Dose-dependent pharmacokinetics of dexamethasone
Abstract
The dose dependency of the pharmacokinetics of dexamethasone and its influence on the endogenous secretion of cortisol has been studied in healthy females. The maximum plasma level occurred between 1.6 and 2.0 h after doses of 0.5-3.0 mg independent of the type of administration. AUC, distribution volume, plasma clearance and cmax did not increase in proportion to the dose but only by the factor of about 0.6-0.7 after the oral administration of 0.5-1.5 mg. Comparatively high values were reached after 3.0 mg i.m. This may be due to reduced bioavailability of the oral doses. Within the first 12 h after the administration of 0.5-3.0 mg, endogenous cortisol secretion was influenced independent of dose. However, the suppressive effect after 24 h was dose dependent and amounted to approximately 24% for 0.5 mg p.o., 62% for 1.5 mg p.o. and 90% for 3.0 mg i.m. In the case of administration every second day, the integral reduction within 24 h after the administration of 0.5 mg dexamethasone was 44 to 65% and for 1.5 mg between 59 and 62%.
Similar articles
-
Fluocortolone: pharmacokinetics and effect on plasma cortisol level.Eur J Clin Pharmacol. 1986;30(4):433-8. doi: 10.1007/BF00607956. Eur J Clin Pharmacol. 1986. PMID: 3743619
-
Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.Eur J Clin Pharmacol. 1988;35(2):177-81. doi: 10.1007/BF00609249. Eur J Clin Pharmacol. 1988. PMID: 2847930
-
Pharmacokinetics and pharmacodynamics of dexamethasone after intravenous administration in camels: effect of dose.Vet Res Commun. 2004 Aug;28(6):525-42. doi: 10.1023/b:verc.0000040243.30199.1f. Vet Res Commun. 2004. PMID: 15509026 Clinical Trial.
-
Effect of dose size on the pharmacokinetics of oral hydrocortisone suspension.J Pharm Sci. 1982 Oct;71(10):1182-5. doi: 10.1002/jps.2600711029. J Pharm Sci. 1982. PMID: 7143223
-
Clinical pharmacokinetics of mizolastine.Clin Pharmacokinet. 2001;40(7):501-7. doi: 10.2165/00003088-200140070-00002. Clin Pharmacokinet. 2001. PMID: 11510627 Review.
Cited by
-
Dexamethasone mimics aspects of physiological acclimatization to 8 hours of hypoxia but suppresses plasma erythropoietin.J Appl Physiol (1985). 2013 Apr;114(7):948-56. doi: 10.1152/japplphysiol.01414.2012. Epub 2013 Feb 7. J Appl Physiol (1985). 2013. PMID: 23393065 Free PMC article. Clinical Trial.
-
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.Support Care Cancer. 2009 Sep;17(9):1177-85. doi: 10.1007/s00520-008-0571-5. Epub 2009 Feb 10. Support Care Cancer. 2009. PMID: 19205755 Free PMC article. Clinical Trial.
-
The effect of glucocorticoids on tendon cell viability in human tendon explants.Acta Orthop. 2009 Jun;80(3):363-7. doi: 10.3109/17453670902988386. Acta Orthop. 2009. PMID: 19421908 Free PMC article.
-
Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.Biopharm Drug Dispos. 2021 May;42(5):191-203. doi: 10.1002/bdd.2266. Epub 2021 Mar 17. Biopharm Drug Dispos. 2021. PMID: 33638217 Free PMC article.
-
Injectable dexamethasone sodium phosphate administered orally? A pharmacokinetic analysis of a common emergency department practice.J Pediatr Pharmacol Ther. 2015 Mar-Apr;20(2):105-11. doi: 10.5863/1551-6776-20.2.105. J Pediatr Pharmacol Ther. 2015. PMID: 25964727 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources